magnifying glass
logo for Apellis

Apellis

Manufacturing · Massachusetts, United States · 476 Employees

Get Full Access

Who is Apellis

Established in 2009, Apellis is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3. They are based in Waltham, Massachusetts.Read More

Headquarters

Headquarters:

100 5th Avenue, Waltham, Massachusetts, 02451, United States
Phone Number

Phone Number:

(617) 977-5700
Revenue

Revenue:

$256 Million
Stock Symbol

Stock Symbol:

APLS
Apellis's Social Media
SIC Code 28,283
NAICS Code 3254,541714
Ticker NASDAQ: APLS
Popular Searches:

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc.

APELLIS PHARMACEUTICALS , INC.

Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc.

Top Competitors of Apellis

Employess
393
revenue
$132 Million

1

Employess
73
revenue
$21 Million

2

Employess
69
revenue
$13 Million

3

Employess
53
revenue
<$5 Million

4

Employess
130
revenue
$147 Million

5

Employess
69
revenue
$14 Million

6

Apellis's Org Chart

Cedric Francois
Cedric Francois

Co-Founder, Chief Executive Officer...

PhonePhoneEmailEmail
Timothy Sullivan
Timothy Sullivan

Chief Financial Officer

PhonePhoneEmailEmail
Pascal Deschatelets
Pascal Deschatelets

Chief Technology Officer

PhonePhoneEmailEmail

PhonePhoneEmailEmail
Illustration of an envelope

Apellis Company Metrics

Company Insights
Employee Growth Rate
Funding
Funding DateRoundAmountInvestors

Nov 19, 2021

Stock Issuance/Offering

$402M

-

Nov 10, 2017

Stock Issuance/Offering

$150M

-

Aug 10, 2017

Series E

$60M

Clough Capital Partners

See More

$721M

Total Funding Amount

$402M

Most Recent Funding Amount

9

Number of Funding Rounds

Revenue
QuarterRevenue

'21 - Q1

288015000

'21 - Q2

288015000

Acquisitions & Subsidiaries

Potentia Pharmaceuticals

See More Acquisitions & Subsidiaries

Apellis's Tech Stack

QuickBooks

By

Intuit

NetSuite

By

Oracle

Achievers

By

Achievers

Cvent

By

Cvent
See more technologies

Apellis News & Media

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson Sells ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Rating) General Counsel David O. Watson sold 10,000 shares of the business's stock in a transaction dated Wednesday, June 22nd. The stock was sold at an average price of $44.51, for a total transaction of $445,100.00. Following the sale, the general counsel now directly owns 115,569 shares in the company, valued at approximately $5,143,976.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which

Apellis Expands R&D Collaboration with Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain

WALTHAM, Mass. and NANTES, France, June 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Affilogic today announced that the companies have expanded their research and development (R&D) collaboration, which was initially formed in 2018, to include the development of Nanofitins® targeting the transferrin receptor (TfR), which enables drugs to be transported across the blood brain barrier and into the central nervous system. TfR-specific Nanofitins, also known as brain

New data reinforce robust efficacy and safety profile of Aspaveli/Empaveli (pegcetacoplan) for PNH at the EHA2022 Congress

Swedish Orphan Biovitrum AB (publ) (Sobi (https://www.sobi.com/en/media)®) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today reported new analyses of phase 3 studies that reinforce the robust efficacy and safety profile of Aspaveli®/Empaveli® (pegcetacoplan) for paroxysmal nocturnal haemoglobinuria (PNH). The data will be presented at the hybrid European Hematology Association (EHA) Congress in Vienna, Austria. New analyses demonstrated that treatment with Aspaveli/Empaveli resul
Subscribe to "Apellis" News

Frequently Asked Questions regarding Apellis

Where are Apellis’s headquarters?

Apellis’s headquarters are in 100 5th Avenue, Waltham, Massachusetts, 02451, United States

What is Apellis’s phone number?

Apellis’s phone number is (617) 977-5700

What is Apellis’s stock symbol?

Apellis’s stock symbol is APLS

What is Apellis’s official website?

Apellis’s official website is www.apellis.com

What is Apellis’s Revenue?

Apellis’s revenue is $256 Million

What is Apellis’s SIC code?

Apellis’s SIC: 28,283

What is Apellis’s NAICS code?

Apellis’s NAICS: 3254,541714

How many employees are working in Apellis?

Apellis has 476 employees

What is Apellis’s industry?

Apellis is in the industry of: Manufacturing, Pharmaceuticals, Business Services

Who are Apellis’s main competitors?

Apellis's main competitors are: Atara Bio, Stealth BioTherapeutics, Tessa Therapeutics, Otonomy

What companies has Apellis acquired?

Apellis has acquired the companies: Potentia Pharmaceuticals

What is Apellis's tech stack?

The technologies that are used by Apellis are: QuickBooks, NetSuite, Achievers, Cvent

Who is Apellis's CEO?

Apellis's CEO is Cedric Francois

Who is Apellis's CFO?

Apellis's CFO is Timothy Sullivan

Who is Apellis's CTO?

Apellis's CTO is Pascal Deschatelets

See more information about Apellis
4.4/5 on G2 Crowd